clinical dermatology

July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.
Abatacept: Pricey, but Effective
Abatacept: Pricey, but EffectiveThe approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
Nitric oxide cream in pipelineA nitric oxide-releasing cream to treat psoriasis and atopic dermatitis is in development.
Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
New therapeutic optionLong-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
Pain control benefits HS patientsAdalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.
Fitting inThe approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.
Considerations when treating children with lasersA laser is a suitable mode of treatment for certain dermatologic conditions in pediatric patients; however, there are certain procedural aspects that physicians should consider when treating younger children.
Pipeline topical reduces epidermolysis bullosa blisteringCastle Creek Pharmaceuticals announced in June 2017 that the first patient had enrolled in its phase 2/3 study assessing the safety and efficacy of its pipeline diacerein 1% ointment to treat epidermolysis bullosa simplex.
Checkpoint inhibitors flourishKey publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist